IN 2022, DAMON RUNYON SCIENTISTS PUSHED THE BOUNDARIES OF WHAT IS POSSIBLE IN SCIENCE TO UNCOVER NEW WAYS TO DETECT, PREVENT, AND TREAT ALL FORMS OF CANCER.

THIS YEAR ALONE, DAMON RUNYON SCIENTISTS:

- Developed an implantable biosensor for early detection of ovarian cancer.
- Launched a clinical trial for the first genetically targeted therapy for cancer prevention, a drug that treats a pre-cancerous blood condition called clonal hematopoiesis.
- Engineered a new kind of CAR T immune cell for the treatment of solid tumors and demonstrated its effectiveness in mice.
- Elucidated the neural pathways that cause the sensation of nausea, paving the way for better strategies to combat this common serious side effect of cancer treatment.

AWARDS AND HONORS

Damon Runyon alumni elected to the National Academy of Sciences (the science "Hall of Fame"): William M. Clemons, Jr., PhD; Gordon J. Freeman, PhD; Linda C. Hsieh-Wilson, PhD; Erik M. Jorgensen, PhD; Alex L. Kolodkin, PhD; Michael J. Lichten, PhD; Joseph D. Mougous, PhD; Julie A. Segre, PhD.

Damon Runyon alumni elected to the American Academy of Arts & Sciences, one of the oldest honorary societies in the country: Arshad B. Desai, PhD; Gordon J. Freeman, PhD; Z. Josh Huang, PhD; Matthew L. Meyerson, MD, PhD.

Former Damon Runyon Fellow **Daniel J. Blair, PhD**, was named a 2022 STAT Wunderkind for his groundbreaking development of a "Lego-like" building kit for the automated synthesis of new molecules that can be the basis of cancer therapies.

Former Damon Runyon Fellow **Pardis C. Sabeti, MD, DPhil**, received a 2022 Time100 Impact Award for her critical role in sequencing viral genomes, including that of SARS-CoV-2.

Former Damon Runyon Clinical Investigator **Eli M. Van Allen, MD**, was awarded the FNIH Trailblazer Prize for his many contributions to the development of precision cancer medicine, particularly with the use of computational biology.

Funding brave and bold.


OUR MISSION

At the Damon Runyon Cancer Research Foundation, we fund high-risk, high-reward cancer research. We identify and enable young scientists who are brilliant, brave, and bold enough to go where others haven't.

RESEARCH PROGRAMS

- We currently fund 187 scientists across 54 academic research institutions.
- In fiscal year 2022, we awarded nearly \$17.2 million in new grants to 58 exceptional scientists, and provided an additional \$1.6 million in stipend increases, extension funding for pandemic-related research delays, and other support.

FINANCIAL INFORMATION



100% OF YOUR DONATION FUNDS BRILLIANT SCIENTISTS.

We pay our low overhead with revenue from Damon Runyon Broadway Tickets and our endowment.

